EGFR and non-small cell lung carcinoma: Finally, based on the newest update of the Graded Prognostic Assessment for lung cancer using molecular markers (Lung-molGPA), the EGFR and anaplastic lymphoma kinase mutation status were included as prognostic factors for patients with NSCLC and BMs [43].